29 patents
Utility
Farnesoid X receptor agonists and uses thereof
3 Oct 23
Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.
Nicholas D. Smith, Steven P. Govek, Karensa L. Douglas, Andiliy G. Lai
Filed: 16 Jun 21
Utility
Crystalline Forms of a Farnesoid X Receptor Agonist
11 May 23
Described herein is the farnesoid X receptor agonist, 4-((4-(1-(tert-butyl)-1H-pyrazol-4-yl)pyridin-2-yl)((4-(4-methoxy-3-methylphenyl)bicyclo[2.2.2]octan-1-yl)methyl)carbamoyl)cyclohexyl 3-hydroxyazetidine-trans-1-carboxylate, including crystalline forms and pharmaceutically acceptable salts, solvates, and formulations thereof.
Nicholas D. SMITH, Robert MANSFIELD
Filed: 17 Mar 21
Utility
Farnesoid X Receptor Agonists for the Treatment of Disease
27 Apr 23
Described herein is the use of farnesoid X receptor (FXR) agonists, alone or in combination with additional therapies, in the treatment or prevention of diseases, conditions, or disorders that would benefit from therapy with a FXR agonist.
Kenneth SONG, Hubert CHEN, Brandee WAGNER, Nicholas D. SMITH
Filed: 17 Mar 21
Utility
Formulations of a Farnesoid X Receptor Agonist
20 Apr 23
Described herein are pharmaceutical formulations of a farnesoid X receptor agonist, 4-((4-(1-(tert-butyl)-1H-pyrazol-4-yl)pyridin-2-yl)((4-(4-methoxy-3-methylphenyl)bicyclo[2.2.2]octan-1-yl)methyl)carbamoyl)cyclohexyl 3-hydroxyazetidine-trans-1-carboxylate, and methods of using such pharmaceutical formulations in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.
Nicholas D. SMITH, Robert MANSFIELD
Filed: 17 Mar 21
Utility
Farnesoid X Receptor Agonists for the Treatment of Disease
13 Oct 22
Described herein are combination therapies with farnesoid X receptor (FXR) agonists, and methods of using such pharmaceutical compositions in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.
Kenneth SONG, Hubert CHEN, Brandee WAGNER
Filed: 9 Jun 22
Utility
Farnesoid X Receptor Agonists and Uses Thereof
24 Mar 22
Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.
Nicholas D. SMITH, Steven P. GOVEK, Johnny Y. NAGASAWA, Karensa L. DOUGLAS, Andiliy G. LAI
Filed: 30 Nov 21
Utility
Farnesoid X Receptor Agonists and Uses Thereof
17 Mar 22
Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.
Nicholas D. SMITH, Steven P. GOVEK, Johnny Y. NAGASAWA
Filed: 22 Nov 21
Utility
Farnesoid X Receptor Agonists and Uses Thereof
24 Feb 22
Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.
Nicholas D. SMITH, Steven P. GOVEK
Filed: 17 Sep 19
Utility
Farnesoid X Receptor Agonists and Uses Thereof
24 Feb 22
Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.
Nicholas D. SMITH, Steven P. GOVEK, Johnny Y. NAGASAWA, Andiliy G. LAI, Karensa L. DOUGLAS
Filed: 17 Sep 19
Utility
Farnesoid X Receptor Agonists for the Treatment of Disease
17 Feb 22
Described herein are combination therapies with famesoid X receptor (FXR) agonists, and methods of using such pharmaceutical compositions in the treatment of conditions, diseases, or disorders associated with famesoid X receptor activity.
Kenneth SONG, Hubert CHEN, Brandee WAGNER, Nicholas D. SMITH
Filed: 17 Sep 19
Utility
Farnesoid X receptor agonists and uses thereof
1 Feb 22
Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.
Nicholas D. Smith, Steven P. Govek, Johnny Y. Nagasawa, Karensa L. Douglas, Andiliy G. Lai
Filed: 14 Mar 18
Utility
Ssao Inhibitors and Uses Thereof
6 Jan 22
Described herein are compounds that are semicarbazide-sensitive amine oxidase (SSAO) inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in treating or preventing a liver disease or condition.
Nicholas D. SMITH, Andrew R. HUDSON, Mi CHEN, Johnny Y. NAGASAWA, Iriny BOTROUS
Filed: 23 Oct 19
Utility
Farnesoid X receptor agonists and uses thereof
4 Jan 22
Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.
Nicholas D. Smith, Steven P. Govek, Johnny Y. Nagasawa
Filed: 12 May 20
Utility
Farnesoid X Receptor Agonists and Uses Thereof
23 Dec 21
Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.
Nicholas D. SMITH, Steven P. GOVEK, Karensa L. DOUGLAS, Andiliy G. LAI
Filed: 16 Jun 21
Utility
Crystalline Forms of a Farnesoid X Receptor Agonist
11 Nov 21
Described herein is the farnesoid X receptor agonist, trans-N-(3-(1-cyclopropyl-1H-pyrazol-4-yl)phenyl)-4-hydroxy-N-((trans-4-(4-methoxy-3-methyl phenyl)cyclohexyl)methyl)cyclohexane-carboxamide, including crystalline forms and pharmaceutically acceptable salts, solvates, and formulations thereof.
Nicholas D. SMITH, Robert MANSFIELD
Filed: 17 Sep 19
Utility
Farnesoid X Receptor Agonists and Uses Thereof
30 Sep 21
Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.
Nicholas D. SMITH, Steven P. GOVEK, Johnny Y. NAGASAWA
Filed: 19 Jan 21
Utility
Farnesoid X receptor agonists and uses thereof
10 Aug 21
Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.
Nicholas D. Smith, Steven P. Govek, Karensa L. Douglas, Andiliy G. Lai
Filed: 17 Sep 19
Utility
Farnesoid X receptor agonists and uses thereof
30 Mar 21
Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.
Nicholas D. Smith, Steven P. Govek, Johnny Y. Nagasawa
Filed: 14 Mar 18
Utility
Farnesoid X receptor agonists and uses thereof
23 Feb 21
Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.
Nicholas D. Smith, Stephen P. Govek, Johnny Y. Nagasawa
Filed: 28 May 20
Utility
Farnesoid X Receptor Agonists and Uses Thereof
4 Feb 21
Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.
Nicholas D. SMITH, Steven P. GOVEK, Johnny Y. NAGASAWA
Filed: 12 May 20